Labidi Soumaya, Mejri Nesrine, Lagha Aymen, Daoud Nouha, El Benna Houda, Afrit Mehdi, Boussen Hamouda
Medical oncology department, Abderrahmane Mami Hospital, University of medicine Tunis-University El Manar, Ariana, Tunisia.
Breast Care (Basel). 2016 Dec;11(6):418-422. doi: 10.1159/000452194. Epub 2016 Nov 15.
Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies have dramatically changed management and outcome of this subgroup, both in adjuvant and metastatic settings. Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). The optimal sequence of the available drugs is still not well established. All this progress raises the question of toxicity that need to be managed, especially with longer survival of patients. In this article, we review different anti-HER2 therapies used in HER2-positive m etastatic breast cancer.
25%至30%的乳腺癌中存在人表皮生长因子受体2（HER2）扩增，且其与侵袭性疾病及较差的生存率相关。多种抗HER2靶向治疗已显著改变了这一亚组患者在辅助治疗和转移情况下的管理及预后。尽管曲妥珠单抗使生存率有所提高，但仍会出现不明的耐药机制，这促使了如拉帕替尼、帕妥珠单抗和曲妥珠单抗 emtansine（T-DM1）等新型抗HER2治疗的研发。现有药物的最佳用药顺序仍未明确确立。所有这些进展引发了对毒性管理问题的关注，尤其是在患者生存期延长的情况下。在本文中，我们综述了用于HER2阳性转移性乳腺癌的不同抗HER2治疗方法。
